John F. DiPersio
Transplant pioneer who developed plerixafor for stem-cell mobilisation and CD7 CAR-T for T-cell leukaemia.
Led development of plerixafor, JAK inhibition for GVHD, and 'fratricide-resistant' CD7-directed CAR-T; former chief of oncology at WashU.
| Title | Journal | Year |
|---|---|---|
| Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma | Blood | 2009 |
Pages like this
not linked directly; found by shared links- TargetCD7
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia, CAR-T cell therapy.
- InstitutionChristian Medical College, Vellore
Shares Multiple myeloma, Acute lymphoblastic leukaemia, Acute myeloid leukaemia, CAR-T cell therapy.
- IdeaHarmonise Europe's hospital exemption for academic cell therapies, with one registry
Shares Multiple myeloma, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- InstitutionSeoul St. Mary's Hospital
Shares Multiple myeloma, Acute lymphoblastic leukaemia, Acute myeloid leukaemia, CAR-T cell therapy.
- InstitutionMasonic Cancer Center, University of Minnesota
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- PersonStephen J. Forman
Shares Acute lymphoblastic leukaemia, Acute myeloid leukaemia, CAR-T cell therapy.
- ProductBelumosudil
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- IdeaOne CAR-T infusion instead of autologous transplant
Shares Autologous stem cell transplant (high-dose therapy), Multiple myeloma, CAR-T cell therapy.